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ACE- Versus Chymase-Dependent Angiotensin II
Generation in Human Coronary Arteries
A Matter of Efficiency?
Beril Tom, Ingrid M. Garrelds, Elizabeth Scalbert, Alexander P.A. Stegmann, Frans Boomsma,
Pramod R. Saxena, A.H. Jan Danser
Objective—The objective of this study was to investigate ACE- and chymase-dependent angiotensin I-to-II conversion in
human coronary arteries (HCAs).
Methods and Results—HCA rings were mounted in organ baths, and concentration-response curves to angiotensin II,
angiotensin I, and the chymase-specific substrate Pro11-D-Ala12–angiotensin I (PA–angiotensin I) were constructed. All
angiotensins displayed similar efficacy. For a given vasoconstriction, bath (but not interstitial) angiotensin II during
angiotensin I and PA–angiotensin I was lower than during angiotensin II, indicating that interstitial (and not bath) angiotensin
II determines vasoconstriction. PA–angiotensin I increased interstitial angiotensin II less efficiently than angiotensin I.
Separate inhibition of ACE (with captopril) and chymase (with C41 or chymostatin) shifted the angiotensin I concentration-
response curve 5-fold to the right, whereas a 10-fold shift occurred during combined ACE and chymase inhibition.
Chymostatin, but not captopril and/or C41, reduced bath angiotensin II and abolished PA–Ang I–induced vasoconstriction.
Perfused HCA segments, exposed luminally or adventitially to angiotensin I, released angiotensin II into the luminal and
adventitial fluid, respectively, and this release was blocked by chymostatin.
Conclusions—Both ACE and chymase contribute to the generation of functionally active angiotensin II in HCAs.
However, because angiotensin II loss in the organ bath is chymase-dependent, ACE-mediated conversion occurs more
efficiently (ie, closer to AT1 receptors) than chymase-mediated conversion. (Arterioscler Thromb Vasc Biol. 2003;23:
251-256.)
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 Pro11-D-Ala12–angiotensin I
ACE inhibitors are widely used for the treatment ofhypertension and heart failure. Their beneficial effects
are believed to be attributable to blockade of the generation of
angiotensin (Ang) II from Ang I. In contrast with this
concept, during chronic ACE inhibitor therapy, plasma and
tissue Ang II levels are unchanged or elevated compared with
the pretreatment situation.1,2 This is not a methodological
artifact.1,2 Several explanations may therefore be put forward.
First, the ACE inhibitor dose may have been too low to obtain
sufficient ACE inhibition. Indeed, high-dose ACE inhibition
seems to be more effective than low-dose ACE inhibition.3
Second, the rise in renin and Ang I that occurs when Ang II
no longer suppresses renin release may overcome ACE
inhibition, at least in part.4,5 Third, ACE upregulation is
known to occur both as a consequence of chronic ACE
inhibitor therapy and during the progression of cardiovascular
diseases.2 Fourth, in vitro studies have shown that there are
alternative enzymes capable of converting Ang I into Ang
II.6–8 The most important of these is the serine protease
chymase. Although one in vivo study recently reported that
the chymase-specific substrate Pro11-D-Ala12–Ang I (PA–Ang
I) induced AT1 receptor–mediated vasoconstriction in human
dorsal hand veins,9 in vivo evidence for chymase-dependent
Ang II generation from native Ang I could not be obtained in
humans.10
In this respect, it is important to realize that the location of
ACE and chymase differs greatly. ACE is a membrane-
associated enzyme that, because of proteolytic cleavage of its
membrane anchor, also occurs in a soluble form in the
extracellular fluid. ACE-expressing cells include endothelial
cells, vascular smooth muscle cells, and cardiomyocytes.11,12
In contrast, chymase is located intracellularly, mainly in the
cytosol of mast cells that are present in the adventitia.13 It has
also been demonstrated in endothelial13 and vascular smooth
muscle cells14 and in the extracellular matrix,13 although not
all studies agree on this matter.15 Based on this distribution
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pattern, it is generally believed that chymase is predominantly
active in the interstitial space.16 However, studies investigat-
ing interstitial Ang II generation could not17 or only partly16
confirm this concept, either because interstitial fluid contains
endogenous inhibitors of chymase (eg, 1-antitrypsin)18 or
because of species differences.19
It was the aim of the present study to provide an explana-
tion for the discrepancy between in vivo and in vitro studies
with regard to the contribution of chymase to Ang I-to-II
conversion in humans. Previous in vitro studies measured
either Ang II generation in tissue homogenates6,19 or evalu-
ated Ang II–mediated constriction after the application of
Ang I or PA–Ang I to intact human arteries.8 In this study,
using human coronary arteries (HCAs), we measured Ang II
release, Ang II–mediated contractile responses, and intersti-
tial Ang II levels after the application of PA–Ang I and native
Ang I with or without inhibitors of ACE and/or chymase. The
underlying assumption of our studies was that because of the
different location of ACE and chymase, chymase-dependent
generation of functionally active Ang II occurs less effi-
ciently, ie, further away from AT1 receptors, and thus
(because of rapid angiotensin metabolism in the interstitial
space) requires more Ang I to lead to vasoconstriction. HCAs
are particularly useful for this purpose, because they contain
ACE, chymase, and AT1 receptors.7
Methods
Drugs
Ang I, Ang II, captopril, chymostatin, PD123319, prostaglandin F2
(PGF2), and substance P were purchased from Sigma. C41 (3-[3,4-
dimethoxyphenylsulfonyl]-1-3,4-dimethylphenylimidazoline-2,4-
dione) was synthesized by Dr M.C. Viaud, Tours, France. Irbesartan
was a gift from Bristol-Myers Squibb, and PA–Ang I (purity 95%)
was a gift from the Institut de Recherches Internationales Servier.
Chymostatin and C41 were dissolved in dimethylsulfoxide, and
irbesartan was dissolved in ethanol. All other compounds were
dissolved in distilled water.
Tissue Collection and Preparation
HCAs were obtained from 17 heart-beating organ donors (6 men, 11
women; ages 18 to 58 years, meanSEM 463 years) who died of
noncardiac causes (14 cerebrovascular accident, 3 head trauma)24
hours before the heart was taken to the laboratory. Hearts were
provided by the Rotterdam Heart Valve Bank after removal of the
aortic and pulmonary valves for transplantation purposes. The study
was approved by the Ethics Committee of the Erasmus MC.
Immediately after circulatory arrest, the hearts were stored in an
ice-cooled sterile organ-protecting solution.7 After arrival in the
laboratory, the HCA (diameter3 to 4 mm) was removed and stored
overnight in a cold, oxygenated Krebs bicarbonate solution of the
following composition (in mmol/L): NaCl 118, KCl 4.7, CaCl2 2.5,
MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, and glucose 8.3; pH 7.4.
Vessels containing macroscopically visible atherosclerotic lesions
were excluded.
Organ Bath Studies
Vessels were cut into segments of 4 mm length, suspended on
stainless steel hooks in 15-mL organ baths containing Krebs bicar-
bonate solution, aerated with 95% O2/5% CO2, and maintained at
37°C. Segments were allowed to equilibrate for at least 30 minutes,
and the organ bath fluid was refreshed every 15 minutes during this
period. Changes in tissue contractile force were recorded with a
Harvard isometric transducer (South Natick). The segments,
stretched to a stable force of 15 mN, were exposed to 30 mmol/L
KCl twice. Subsequently, segments were exposed to 100 mmol/L
KCl to determine the maximal contractile response to KCl. The
segments were then allowed to equilibrate in fresh organ bath fluid
for 30 minutes. Next, segments were preincubated for 30 minutes
with or without the AT1 receptor antagonist irbesartan (1 mol/L),
the AT2 receptor antagonist PD123319 (1 mol/L), the chymase
inhibitor chymostatin (100 mol/L), the ACE inhibitor captopril (10
mol/L), and/or the chymase inhibitor C41 (10 mol/L). Thereafter,
concentration response curves (CRCs) to Ang I, Ang II, and PA–Ang
I were constructed. Endothelial integrity was verified at the end of
each experiment by observing relaxation to 1 nmol/L substance P
after precontraction with 1 mol/L PGF2.
To measure Ang II in organ bath fluid, a 50 L-sample was
obtained from the organ bath at the time the vasoconstrictor response
had reached a plateau. Samples were rapidly mixed with 10 L
angiotensinase inhibitor solution7 and stored at 80°C. Tissue Ang
II was measured in a limited number of vessel segments only. Based
on previous measurements in vessel segments showing that vascular
Ang II remains stable for at least 1 hour after the addition of Ang I,20
the segments were removed 1 hour after the addition of 1 mol/L
Ang I or PA–Ang I, washed in fresh Krebs solution, dried on tissue
paper, frozen in liquid nitrogen, and stored at 80°C.
Perfusion Studies
Vessels were cut into segments of 1 to 2 cm length. Side branches,
if present, were tied off with silk sutures. Each segment was mounted
horizontally in a double-jacketed 4-mL organ bath and perfused from
a 6-mL reservoir using a roller pump (Ismatec IPS; flow 1 mL/min).
Both organ bath and reservoir contained Krebs bicarbonate solution,
aerated with 95% O2/5% CO2, and were maintained at 37°C. The
perfusate was collected in the reservoir and reperfused through the
vessel, thus creating a closed perfusion circuit,21 allowing both
adventitial (ie, into the bath) and luminal (ie, into the reservoir) drug
application. Ang I (1 mol/L) was added to the bath or the reservoir,
under control conditions, in the presence of 10 mol/L captopril and
in the presence of 10 mol/L captopril plus 100 mol/L chymosta-
tin, respectively. Luminal and adventitial fluid samples (50 L) were
obtained as described above immediately before and 30 and 60
minutes after the addition of Ang I. Before each subsequent Ang I
application, bath and reservoir fluid were refreshed. All experiments
were performed in the presence of 1 mol/L irbesartan to prevent
AT1 receptor–mediated vasoconstriction.
Biochemical Measurements
Ang II in organ bath and reservoir fluid was measured with sensitive
radioimmunoassays.7 Ang II in vessel segments was measured by
radioimmunoassay after SepPak extraction and HPLC separation.5
Data Analysis
Data are given as meanSEM. Contractile responses are expressed
as a percentage of the maximal contraction to 100 mmol/L KCl
(63.94.9 mN, n11). CRCs were analyzed as described earlier7 to
obtain pEC50 (10log EC50) values. Statistical analysis was per-
formed by one-way ANOVA, followed by post hoc evaluation
(according to Tukey or Dunnett where appropriate). P0.05 was
considered significant.
Results
Organ Bath Studies
Ang I, Ang II, and PA–Ang I displayed similar maximal
effects (Figure 1, Table). Irbesartan, but not PD123319,
prevented the PA–Ang I–induced vasoconstriction (Figure 1),
indicating that its contractile effects, like those of Ang I in
this model,7 are mediated via AT1 receptors. PA–Ang I was
less potent (P0.05) than Ang I and Ang II. At the moment
of constriction, Ang II levels in the organ bath fluid during
both Ang I and PA–Ang I amounted to5% of the Ang I and
PA–Ang I levels (Figure 2), and the pEC50 values calculated
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from these Ang II levels (9.200.25 and 8.900.15 for Ang
I and PA–Ang I, respectively; PNS) were 20 to 40 times
higher (P0.01) than the pEC50 for Ang II. Thus, for a given
constriction, the organ bath fluid Ang II level was lower
during Ang I and PA–Ang I application than during Ang II
application.
Captopril (PNS), C41 (PNS), and chymostatin
(P0.05) modestly shifted the Ang I CRC to the right,
whereas a 5- to 10-fold rightward shift (P0.01) occurred
during C41 plus captopril (Figure 3, Table). Chymostatin, but
not captopril and/or C41, abolished the effects of PA–Ang I.
C41 did not affect the Ang II CRC (Table).
Chymostatin reduced the Ang II release into the organ bath
during Ang I and PA–Ang I application by 75% (P0.05,
Figure 4). Captopril, C41, or their combination did not
significantly affect the Ang II levels in the organ bath during
Ang I and PA–Ang I application.
Interstitial Ang II and Vasoconstriction
One hour after the application of 1 mol/L Ang I to the organ
bath, the level of Ang II in the arterial segment (wet weight
242 mg; n24) was 18.74.3 pmol/g wet weight (n4).
Vascular Ang II was not affected by irbesartan (18.96.0
pmol/g; n4) or PD123319 (29.412.1 pmol/g; n4). Com-
parable observations were made after the application of 1
mol/L PA–Ang I (vascular Ang II, respectively, 11.41.4,
9.91.4 and 7.62.4 pmol/g; n4 for each condition),
although the vascular Ang II levels during PA–Ang I were 2
to 4 times (P0.01) lower than during Ang I. The organ bath
fluid levels of Ang II in these experiments were not affected
by irbesartan or PD123319 and resembled those in Figure 4
(data not shown).
The lack of effect of irbesartan and PD123319 on vascular
Ang II indicates that most tissue Ang II is not bound to either
cell surface or internalized AT1 or AT2 receptors and thus is
located extracellularly (ie, in interstitial fluid). Because inter-
stitial fluid accounts for 15% of tissue weight,20 it can be
calculated that the interstitial Ang II levels during Ang I and
PA–Ang I application are 148.735.6 and 64.35.1 nmol/L
(mean of all measurements, including those with AT receptor
blockers), respectively. This is 9.44.2 and 5.11.5
(P0.05 for difference) times higher than the organ bath fluid
Ang II levels at the time of vasoconstriction. The interstitial
Ang II levels during Ang II application are as high as the Ang
II levels in the organ bath.20 The right panel of Figure 2
illustrates the consequence of this concept. It is clear that for
a given vasoconstriction, the interstitial Ang II levels during
Ang I, PA–Ang I, and Ang II are comparable. However, it
Figure 1. Left, contractions of HCAs to Ang I (‘), Ang II (),
and PA–Ang I (). Contractions (meanSEM, n8) are
expressed as a percentage of the response to 100 mmol/L KCl.
Right, contractions of HCAs to PA–Ang I in the absence () or
presence of irbesartan () or PD123319 (). Contractions
(meanSEM, n3) are expressed as a percentage of the
response to 100 mmol/L KCl.
pEC50 and Emax of Ang I, Ang II, and PA-Ang I in Human Coronary Arteries With or Without Inhibitors
Ang I PA–Ang I Ang II
Inhibitor pEC50
Emax, % of
100 mmol/L K pEC50
Emax, % of
100 mmol/L K pEC50
Emax, % of
100 mmol/L K
None 7.350.13 234.4 6.870.14* 172.7 7.630.05 246.3
10 mol/L captopril 7.250.13 203.9 7.000.12 172.9
10 mol/L C41 7.140.12 183.7 6.750.11 142.7 7.550.06 173.8
10 mol/L captopril10 mol/L C41 6.580.05† 216.2 6.670.07 173.7
100 mol/L chymostatin 6.900.13‡ 184.4 6‡ 6.71.7‡§
Data are meanSEM of 8 experiments.
*P0.05 vs Ang I and Ang II. †P0.05 and ‡P0.01 vs none. §Contractile response at the highest concentration of Ang I that
was tested.
Figure 2. Contractions of HCAs versus organ bath fluid (left)
and interstitial (right) Ang II levels at the time of constriction
after the addition of Ang I (‘), Ang II (), and PA–Ang I ().
Contractions (meanSEM, n8) are expressed as a percentage
of the response to 100 mmol/L KCl.
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requires more PA–Ang I than Ang I to reach a certain
interstitial Ang II level.
Perfusion Studies
Luminal Ang I application resulted in the appearance of Ang
II in luminal but not adventitial fluid, whereas adventitial Ang
I application resulted in the appearance of Ang II in adven-
titial but not luminal fluid (Figure 5). Ang II levels increased
over time and were 4 times higher in adventitial fluid after
adventitial Ang I application than in luminal fluid after
luminal Ang I application. Chymostatin plus captopril, but
not captopril alone, fully prevented luminal and adventitial
Ang II release.
Discussion
The present study compares, in HCAs mounted in organ
baths, the vasoconstrictor efficiency of Ang II generated by
ACE and by chymase, using both native Ang I and the
chymase-specific substrate PA–Ang I. The results show that
Ang I is 5 to 10 times more potent than PA–Ang I and that
Ang II release into the organ bath is almost exclusively
chymase-dependent. Furthermore, chymase inhibition with
chymostatin is sufficient to block the vasoconstrictor effects
of PA–Ang I, whereas in the case of Ang I, combined
inhibition of ACE and chymase results in a better blockade of
vasoconstriction than separate inhibition of ACE and chy-
mase. Thus, both ACE and chymase contribute to the gener-
ation of functionally active Ang II from Ang I in isolated
HCAs, but the generation of Ang II by chymase is far less
efficient, resulting in loss of Ang II into the organ bath fluid,
thereby requiring more Ang I to obtain a certain degree of
constriction. These data may offer an explanation for the
discrepancy between in vitro and in vivo findings with regard
to the enzymes contributing to Ang I-to-II conversion.7,8,10
In agreement with previous in vitro7 and in vivo10 studies,
Ang I was as potent as Ang II in the present experimental
setup. This is remarkable in view of the low Ang II concen-
trations that were detected in the organ bath fluid during the
construction of the Ang I CRC. In fact, for a given constric-
tion, the organ bath fluid concentrations during Ang I were
40 times lower than those during Ang II. The explanation
for this apparent discrepancy, confirmed in the present study,
is that the vascular interstitial Ang II concentrations at
equimolar Ang I and Ang II levels are comparable20 and thus
that vasoconstriction is determined by interstitial rather than
organ bath fluid Ang II. The findings on PA–Ang I parallel
those on Ang I. Taken together, therefore, the levels of Ang
II in the organ bath fluid are not representative of the Ang II
levels seen by the receptor and rather represent nonfunctional
Ang II that has been lost in the organ bath. Similarly,
coronary constriction in the isolated perfused rat heart during
exposure to either renin or Ang II did not relate to the Ang II
levels in the effluent, suggesting that also in this preparation
Figure 4. Ang II levels in organ bath fluid measured at the
moment of contraction of HCAs during the construction of
CRCs to Ang I (left) and PA–Ang I (right) in the absence (control;
) or presence of chymostatin (), captopril (‘), C41 (»), or
captoprilC41 (). Data are meanSEM of 8 experiments.
Figure 5. Luminal and adventitial Ang II levels after the luminal
(left panels) or adventitial (right panels) application of Ang I (1
mol/L) under control conditions (), in the presence of capto-
pril (‘), or in the presence of captoprilchymostatin (). In the
panels providing the control data only, Ang II was undetectable
under all conditions. SEM, if not shown, is smaller than the
symbol. Data are meanSEM of 5 experiments (*P0.05 vs
control).
Figure 3. Contractions of HCAs to Ang I (left) and PA–Ang I
(right) in the absence () or presence of chymostatin (), capto-
pril (‘), C41 (»), or captoprilC41 (). Contractions
(meanSEM, n8) are expressed as a percentage of the
response to 100 mmol/L KCl.
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(representative for resistance vessels, as opposed to the
conduit-type artery used in the present study), constriction is
determined by tissue (interstitial) Ang II.22
Chymostatin, but none of the other inhibitors used in this
study (including the chymase-selective inhibitor C41), pre-
vented the release of Ang II into the organ bath fluid during
the application of both Ang I and PA–Ang I. The lack of
effect of 10 mol/L C41, despite its potent inhibitory effects
toward chymase in human heart homogenates (IC50 22 nmol/
L),8 suggests either that C41 does not have sufficient access
to chymase in intact tissue or that chymostatin, being a
nonselective chymase inhibitor, inhibits alternative convert-
ing enzymes (eg, cathepsin G). The latter conclusion would
also imply that PA–Ang I is not a chymase-specific substrate,
as has already been suggested based on studies in rat
arteries.23 However, in humans using aprotinin (an inhibitor
of cathepsin G but not chymase), evidence for cathepsin
G–mediated Ang I-to-II conversion could not be obtained.6
Thus, the most likely explanation for the limited effect of C41
compared with chymostatin, in agreement with a recent study
in human mammary arteries,8 is that, at the concentration we
used, its inhibitory capacities are more modest than those of
chymostatin. It does have access to chymase, as evidenced by
our observation that the Ang I CRC is shifted to the right in
the presence of captopril and C41, but not when these
inhibitors are given separately. The limited availability of
C41 prevented us from constructing Ang I and PA–Ang I
CRCs at higher C41 concentrations.
Captopril, at a dose that is sufficient to obtain complete
ACE inhibition,21,24 did not reduce Ang II release in the organ
bath. In contrast, ACE inhibition resulted in complete sup-
pression of Ang II release during incubation of porcine
arteries with Ang I and during perfusion of rat hearts with
renin or Ang I.20–22 Thus, although ACE-dependent Ang II
release does occur in vitro, in human arteries it is apparently
modest compared with the chymase-dependent Ang II re-
lease. In view of the fact that chymase is predominantly
located adventitially,13 whereas ACE is largely present on
endothelial cells,12 we attempted to distinguish endothelial
from adventitial Ang II release by quantifying Ang II in
luminal and adventitial fluid obtained from perfused HCAs
after the application of Ang I to either the luminal or the
adventitial compartment. The data confirm the concept that
chymase is located predominantly adventitially, because the
chymase-dependent Ang II release after adventitial Ang I
application was 4 times higher than that after luminal Ang II
release. Angiotensin diffusion from the adventitial compart-
ment to the luminal compartment or vice versa did not occur,
in agreement with earlier work suggesting that such exchange
probably takes place at the level of the capillaries.21,25
Remarkably, however, ACE inhibition did not affect luminal
Ang II release. This contrasts with in vivo studies measuring
venous Ang II levels during arterial Ang I infusion,10 as well
as with studies in Ang I–perfused porcine arteries.21 Because
chymase has been demonstrated in endothelial cells,13 release
of this chymase under in vitro conditions may have resulted
in a greater contribution of chymase to endothelial Ang II
release ex vivo, thus making it impossible to detect ACE-
dependent Ang II release. Along the same lines of reasoning,
the contribution of adventitial chymase is probably also larger
ex vivo. Explanations for the greater role of chymase in vitro
than in vivo are, first, that tissue storage and handling may
have resulted in chymase release from intracellular storage
sites and, second, the absence of endogenous chymase inhib-
itors (eg, 1-antitrypsin and secretory leukocyte protease
inhibitor)18,26 in isolated vessel preparations.
Irrespective of the cause of the major contribution of chymase
to Ang II generation in isolated HCAs, it is clear that ACE is
located more strategically than chymase, ie, closer to AT1
receptors, thereby allowing it to contribute to Ang II generation
in a highly efficient manner, with little or no loss of Ang II to the
organ bath. The higher interstitial Ang II levels during Ang I
application compared with PA–Ang I application confirm this
concept. Similarly, efficient ACE-dependent Ang II generation
has been demonstrated in porcine femoral arteries and in
cultured rat cardiomyocytes.20,27
The question arises whether chymase does play a role at all
in vivo. In view of its location (adventitial, largely intracel-
lular), it may not face the same Ang I levels as ACE.
Moreover, endogenous inhibitors in interstitial fluid suppress
its activity, thereby counteracting its more efficient cleavage
of Ang I compared with ACE (kcat/Km 198 versus 125
mol/L1 min1).6,18,26 Thus, it will probably only generate
Ang II when Ang I levels are high, eg, during ACE inhibition.
In support of this concept, all in vivo studies using the
chymase-specific substrate PA–Ang I9,23,28,29 show that the
concentrations of this substrate required to induce vasocon-
striction are 10 to 100 times higher than the concentrations of
Ang I required to reach the same degree of vasoconstriction,
despite the fact that the affinities of Ang I and PA–Ang I for
chymase are similar.8 Furthermore, even when Ang II is
generated by adventitial chymase at high Ang I levels, its
functional activity may be limited, because it is will be
exposed to significant metabolism on its way to AT1
receptors.17,30
In conclusion, ACE-dependent Ang II generation results in
more efficient AT1 receptor stimulation than chymase-
dependent Ang II generation, and the importance of the latter
pathway is overestimated under in vitro conditions.
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